1. Seung KJ, Omatayo DB, Keshavjee S, Furin JJ, Farmer PE, Satti H. Early Outcomes of MDR-TB Treatment in a High HIV-Prevalence Setting in Southern Africa. PLOS ONE. 2009;4(9):e7186. [cited 2017 Sept 8] Available from:
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0007186
2. Berhan A, Berhan Y, Yizengaw D. A meta-analysis of drug resistant tuberculosis in sub-Saharan Africa: how strongly associated with previous treatment and HIV co-infection? Ethiop J Health Sci. 2013;23(3):271–82 Available from:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847537/
. Accessed 14 Sept 2017
3. Falzon D, Schünemann HJ, Harausz E, González-Angulo L, Lienhardt C, Jaramillo E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49(3) Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399349/
. Accessed 12 May 2018.
4. Cain KP, Marano N, Kamene M, Sitienei J, Mukherjee S, Galev A, et al. The movement of multidrug-resistant tuberculosis across Borders in East Africa needs a regional and global solution. PLoS Med. 2015;12(2):e1001791. [cited 2017 Sep 8] Available from:
http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001791
5. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9(8) Available from:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429397/
. Accessed 14 Sept 2017.